Schott supports Russia’s ‘Pharma 2030’ strategy

“With this strategy, the Russian government aims to encourage the development of drugs and their production while seizing export opportunities”

As part of a major global investment incentive, Schott, manufacturer of high-quality pharma packaging, has invested in high-speed machines at the Russian site Zavolzhye. With the nearly €10m investment, up to 40 jobs will be created. Schott Russia relies on the latest technology according to international standards. "The glass packaging will even get better and safer. In addition, the production will get more energy-efficient", said Frank Bellemans, VP Global Operations within the Business Unit Pharmaceutical Systems at Schott.

“Also, our customers from the pharma industry need more and better data to validate our products and manufacturing processes. By investing in digitalisation, we are meeting future requirements already soon.”

To mark the 10th anniversary of its Zavolzhye manufacturing site, Schott has again renewed its commitment to Russia. Site Manager Denis Nikitin said: "The move will further enable an even stronger integration into the global Schott production network. It will support our joint fight against COVID and the secure supply to our Russian customers. It will also strengthen the production ability in the spirit of the current Russian ‘Pharma 2030’ strategy." With this strategy, the Russian government aims to encourage the development of drugs and their production while seizing export opportunities. Local access to high-quality packaging is crucial to reach this goal.

“Our intention is to keep working closely with the Russian pharma industry and support their growth plans by offering just the right packaging solutions," said Denis Nikitin. The site manufactures vials and ampoules made of borosilicate glass and serves the pharma industry to safely package, transport, and store medications.

Schott works with the industry on the development of future-oriented packaging solutions. These include the iQ ready-to-use concept for aseptic filling of medications and a range of ultra-pure pharmaceutical vials to meet the exacting drug stability needs of low-fill drugs. Designed as a modular concept, Schott Everic enables pharmaceutical companies to package biologic drugs while supporting today's quality requirements of fill and finish lines.

The site in Zavolzhye carries out its work in line GMP principles, including modern systems and machines, well-trained employees, and respective guidelines for quality assurance.

Featured Companies

Schott (more information, website)